Abstracts tagged "IgG4 Related Disease"

Abstract Number: 1167 • ACR Convergence 2025
Clinical Characteristics and Outcomes of IgG4-Related Disease Patients Who Chose Watchful Observation without Treatment Intervention: A Single-Center Study
Kanako Chujo¹, Hiromi Shimada², Shusaku Nakashima², Taichi Miyagi¹, Koichi Sugihara², Yusuke Ushio¹, Mao Mizusaki², Naoto Manabe¹, Mayuko Wada², Risa Wakiya³, Hiroki Ozaki⁴ and Hiroaki Dobashi², ¹Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan, ²Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Kagawa, Japan, ³Division of Rheumatology, Departent of Internal Medicine, Toho University School of Medicine, Tokyo, Japan, ⁴KKR Takamatsu Hospital, Takamatsu, Kagawa, Japan
Background/Purpose: Treatment of IgG4-related disease (IgG4-RD) is recommended for patients with severe organ involvement or for patients with reduced quality of life even in the…
Abstract Number: 2546 • ACR Convergence 2025
Diagnostic Journey, Clinical Burden, And Quality Of Life Of Patients With IGg4-Related Disease: Results Of A Cross-Sectional Survey Of Patients And Physicians In The United States
Yasmin Hernandez-Barco¹, Jenny Y. Park², Rajvi Wani³, Andrea Meyers⁴, Matthew Charles Baker⁵, Leonard Calabrese⁶, Kristina Patterson², Hannah Connolly⁷, Shiva Lauretta Birija⁷ and Emma Culver⁸, ¹Massachusetts General Hospital; Harvard Medical School, Boston, MA, ²Amgen Inc., Thousand Oaks, CA, ³Amgen Canada Inc., Mississauga, ON, Canada, ⁴Amgen Canada Inc., Thousand Oaks, ON, Canada, ⁵Stanford University, Menlo Park, CA, ⁶Cleveland Clinic, Cleveland, OH, ⁷Adelphi Real World, Bollington, United Kingdom, ⁸John Radcliffe Hospital; University of Oxford, Oxford, United Kingdom
Background/Purpose: IgG4-related disease (IgG4-RD) is a chronic immune-mediated fibroinflammatory condition characterized by fibrosis and organ damage. Although IgG4-RD is increasingly recognized, real-world clinical burden remains…
Abstract Number: 1163 • ACR Convergence 2025
Clinical and Biomarker Characteristics of Inebilizumab-Treated Participants Who Experienced an IgG4-RD Flare During the Phase 3 MITIGATE Trial
John Stone¹, Emma Culver², Arezou Khosroshahi³, Wen Zhang⁴, Emanuel Della Torre⁵, Kazuichi Okazaki⁶, Yoshiya Tanaka⁷, Matthias Lohr⁸, nicolas schleinitz⁹, Fernando Martinez-Valle¹⁰, Manu Nayar¹¹, Vinciane Rebours¹², Cory Perugino¹³, Kristen Clarkson¹⁴, Theresa Alexander¹⁴, Xinxin Dong¹⁴, Qian Huang¹⁴, Sue Cheng¹⁴ and Daniel Cimbora¹⁴, ¹Massachusetts General Hospital , Harvard Medical School, Concord, MA, ²John Radcliffe Hospital; University of Oxford, Oxford, United Kingdom, ³Emory University, Atlanta, GA, ⁴Peking Union Medical College Hospital, Dong Cheng Qu, China (People's Republic), ⁵IRCCS San Raffaele Scientific Institute, Milan, Italy, ⁶Kansai Medical University Kori Hospital, Osaka, Japan, ⁷University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁸Karolinska Institutet, Stockholm, Sweden, ⁹Aix Marseille university, AP-HM, Marseille, France, ¹⁰Vall d’Hebron Hospital, Barcelona, Spain, ¹¹Freeman Hospital, Newcastle upon Tyne, United Kingdom, ¹²Beaujon Hospital, AP-HP, Université Paris-Cité, Clichy, France, ¹³Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹⁴Amgen, Thousand Oaks, CA
Background/Purpose: IgG4-RD is a rare, chronic, fibroinflammatory disorder characterized by recurrent flares that can affect any organ and lead to permanent tissue damage. Inebilizumab (INEB)…
Abstract Number: 2531 • ACR Convergence 2025
Coronary periarteritis in IgG4-Related Disease
Georges El Hasbani¹, Daniel Larson², Matthew Koster¹ and Kenneth Warrington¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester
Background/Purpose: IgG4-related disease (IgG4-RD) is characterized by chronic inflammation and fibrosis, which can affect multiple organs, especially the pancreas, salivary glands, and retroperitoneum (1). It…
Abstract Number: 1154 • ACR Convergence 2025
Assessment Of Damage Using The IgG4-Related Disease Damage Index.
Eduardo Martin-Nares¹ and Gabriela Hernandez-Molina², ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Federal District, Mexico
Background/Purpose: IgG4-related disease (IgG4-RD) is a chronic fibroinflammatory disorder affecting multiple organs, often leading to irreversible damage. Standardized tools like the IgG4-RD Damage Index (DI)…
Abstract Number: 2530 • ACR Convergence 2025
Broad Screening of Inflammation-Associated Proteins Identifies Serum CCL19 and CCL2 as Versatile Biomarkers of Disease Activity in IgG4-Related Disease
Federica Bonaso¹, Bohang Jiang², Laura J. Yockey³, Jesse Akaa⁴, Ian Doyle⁴, Evan Hsu⁵, Courtney Leson⁶, Grace McMahon⁷, Isha Jha⁷, Sydney Montesi⁷, Guy Katz⁷, Shiv Pillai⁸, Pui Lee⁵, John Stone⁹, Zachary Wallace¹⁰ and Cory Perugino¹¹, ¹University of Brescia, ASST Spedali Civili of Brescia, Massachusetts General Hospital, Monza, Italy, ²MGH, Boston, MA, ³MGH, Charlestown, MA, ⁴Massachusetts General Hospital (MGH - Mass General) (MGB), Boston, MA, ⁵Boston Children's Hospital, Newton, MA, ⁶Boston Children's Hospital, Boston, ⁷Massachusetts General Hospital, Boston, MA, ⁸Harvard Medical School, Cambridge, MA, ⁹Massachusetts General Hospital , Harvard Medical School, Concord, MA, ¹⁰Massachusetts General Hospital, Newton, MA, ¹¹Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is a chronic immune-mediated disease characterized by mass-forming lesions and organ dysfunction. The smoldering tempo and often asymptomatic nature of IgG4-RD…
Abstract Number: 1036 • ACR Convergence 2025
Factors Associated With Long-term Remission After Drug Discontinuation In IgG4-related Disease: A 3-Year Rule
Yifei Wang¹, Yuxue Nie², Jingna Li³, Jialei Zhang⁴, Qinhuan Luo¹, Xinli Yang⁵, Jialing Jiang¹, Nianyi Zhang⁶, Linyi Peng⁷, Yunyun Fei⁶, Jiaxin zhou⁴ and Wen Zhang⁸, ¹Peking Union Medical College, Beijing, China (People's Republic), ²Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China, Dong Cheng Qu, China (People's Republic), ³Peking Union Medical College, Dong Cheng Qu, Beijing, China, ⁴Peking Union Medical College Hospital, Beijing, China (People's Republic), ⁵Peking Union Medical College, Dong Cheng Qu, China (People's Republic), ⁶Peking Union Medical College Hospital, Beijing, Beijing, China (People's Republic), ⁷PEKING UNION MEDICAL COLLEGE HOSPITAL, Beijing, Beijing, China, ⁸Peking Union Medical College Hospital, Dong Cheng Qu, China (People's Republic)
Background/Purpose: IgG4-related disease (IgG4-RD) is a chronic fibroinflammatory disorder with multi-organ involvement and elevated serum IgG4 levels. Glucocorticoids (GC) with or without immunosuppressants (IM) are…
Abstract Number: 2529 • ACR Convergence 2025
IgG4-Related Disease Paravertebral and Ureteropelvic Mass Presentations are Linked to Specific Disease Features
Federica Bonaso¹, Grace McMahon², Isha Jha², Guy Katz², Zachary Wallace³, John Stone⁴ and Cory Perugino⁵, ¹University of Brescia, ASST Spedali Civili of Brescia, Massachusetts General Hospital, Monza, Italy, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Newton, MA, ⁴Massachusetts General Hospital , Harvard Medical School, Concord, MA, ⁵Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is a chronic immune-mediated disease characterized by mass-forming fibrotic lesions. The aim of this work was to characterize the overall clinical…
Abstract Number: 0992 • ACR Convergence 2025
FoxP3Lo CD4+ T cells are functionally suppressive and expanded in the immune-mediated fibrotic diseases IgG4-related disease and systemic sclerosis
Laura J. Yockey¹, Ian Doyle², Thomas Guy³, Devanshi Trivedi², Chinmay Gadiraju⁴, Federica Bonaso⁵, Jesse Akaa², Alison Puri⁶, Zachary Wallace⁷, Guy Katz⁸, Sydney Montesi⁸, John Stone⁹, Flavia Castelino⁸, Shiv Pillai¹⁰, Andrew Luster¹¹, Vinay S. Mahajan¹² and Cory Perugino¹³, ¹MGH, Charlestown, MA, ²Massachusetts General Hospital (MGH - Mass General) (MGB), Boston, MA, ³Ragon Institute of MGH, MIT and Harvard/ Royal Prince Alfred Hospital Sydney, Sydney, Australia, ⁴Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, ⁵University of Brescia, ASST Spedali Civili of Brescia, Massachusetts General Hospital, Monza, Italy, ⁶Boston University, Brookline, MA, ⁷Massachusetts General Hospital, Newton, MA, ⁸Massachusetts General Hospital, Boston, MA, ⁹Massachusetts General Hospital , Harvard Medical School, Concord, MA, ¹⁰Harvard Medical School, Cambridge, MA, ¹¹Massachusetts General Hospital, Charlestown, MA, ¹²Brigham and Women's Hospital, Boston, MA, ¹³Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: The absence of regulatory T cells (Tregs) results in multiorgan autoimmunity in the context of monogenic “Tregopathies,” but their role in mediating polygenic autoimmune…
Abstract Number: 2528 • ACR Convergence 2025
Broad Screening of the Human Proteome Identifies a Cassette of Six Autoantigens that Distinguishes IgG4-Related Disease
Federica Bonaso¹, Zhenrui Zhang², Mahilan Guha³, Ian Doyle⁴, Jesse Akaa⁴, Grace McMahon⁵, Isha Jha⁵, Sydney Montesi⁵, Thomas Guy⁶, Guy Katz⁵, Zachary Wallace⁷, John Stone⁸, Vinay S. Mahajan⁹, Shiv Pillai¹⁰ and Cory Perugino¹¹, ¹University of Brescia, ASST Spedali Civili of Brescia, Massachusetts General Hospital, Monza, Italy, ²Ragon Institute of Mass General Brigham, MIT, and Harvard, Boston, ³Montgomery Blair High School, Brigham and Women’s Hospital, Boston, ⁴Massachusetts General Hospital (MGH - Mass General) (MGB), Boston, MA, ⁵Massachusetts General Hospital, Boston, MA, ⁶Ragon Institute of MGH, MIT and Harvard/ Royal Prince Alfred Hospital Sydney, Sydney, Australia, ⁷Massachusetts General Hospital, Newton, MA, ⁸Massachusetts General Hospital , Harvard Medical School, Concord, MA, ⁹Brigham and Women's Hospital, Boston, MA, ¹⁰Harvard Medical School, Cambridge, MA, ¹¹Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is a chronic immune-mediated disease typified by mass-forming lesions. Self-antigens driving the oligoclonal expansion of plasmablasts have previously been reported. However,…
Abstract Number: 0910 • ACR Convergence 2025
Development of Four Distinct Human IgG4-Producing Mouse Models Recapitulating IgG4-Related Disease
MIN GANG KIM¹, JINA YEO², HEA RIM KANG³, JAE HYUN MOON³, Seon Uk Kim⁴, SeoYoon Ban⁵, MI HYEON KIM⁶ and Eun Young Lee⁷, ¹Seoul National University College of Medicine, Seoul, Republic of Korea, ²Division of Rheumatology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Republic of Korea, ³Seoul National University College of Medicine, Jongno-gu, Seoul, Republic of Korea, ⁴Seoul National University, Jongno-gu, Seoul, Republic of Korea, ⁵Department of Cancer biology, Graduate School of College of Medicine, Seoul National University, Korea, Seoul, Republic of Korea, ⁶Hallym university dongtan sacred heart hospital, Seocho-gu, Seoul, Republic of Korea, ⁷Seoul National University College of Medicine, Seoul, South Korea
Background/Purpose: IgG4-related disease (IgG4RD) is an immune-mediated fibroinflammatory condition characterized by multi-organ involvement, elevated serum IgG4, and IgG4-positive plasma cell infiltrates that form tumor-like lesions…
Abstract Number: 2051 • ACR Convergence 2025
Clinical Burden of Illness Among Patients with Immunoglobulin-G4-Related Disease in the United States
Sushmitha Inguva¹, Emma Culver², Pallavi Rane¹, Laura Moore-Schiltz³, melissa rosen⁴, Kristina Patterson⁴, Donna McMorrow³, Zulkarnain Pulungan⁵, Yasmin Hernandez-Barco⁶ and John Stone⁷, ¹Amgen Inc., Thousand Oaks, ²John Radcliffe Hospital; University of Oxford, Oxford, United Kingdom, ³Inovalon, Bowie, MD, ⁴Amgen Inc., Thousand Oaks, CA, ⁵Inovalon, Bowie, ⁶Massachusetts General Hospital; Harvard Medical School, Boston, MA, ⁷Massachusetts General Hospital , Harvard Medical School, Concord, MA
Background/Purpose: Immunoglobulin G4-related disease (IgG4-RD) is a multi-organ, immune-mediated condition. Timely treatment is critical, as disease flares often result in increased inflammation and organ damage.…
Abstract Number: 0421 • ACR Convergence 2025
Inflammatory Orbital Diseases: Pediatric Case Series From a Tertiary Care Center
Rasha Elrefai¹, Katherine Williams² and Hannah Bradfield³, ¹Baylor College of Medicine, Houston, TX, ²Texas Children's Hospital, Houston, TX, ³Baylor College of Medicine/Texas Children's Hospital, Houston, TX
Background/Purpose: Orbital inflammatory diseases in the pediatric population present diagnostic and therapeutic challenges due to variable clinical manifestations, limited prospective data, and lack of standardized…
Abstract Number: 2033 • ACR Convergence 2025
Complement Fragments are Deposited in the Submandibular Glands in IgG4-Related Disease
Guy Katz¹, Judith Ferry¹, Grace McMahon¹, Isha Jha², Claire Galand³, Fei Liu⁴, Shelia Violette⁴, Jason Campagna⁴, Ana Fernandes¹, Cory Perugino⁵ and John Stone⁶, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, ³Q³² Bio Inc,, Waltham, MA, ⁴Q³² Bio Inc, Waltham, MA, ⁵Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁶Massachusetts General Hospital , Harvard Medical School, Concord, MA
Background/Purpose: Hypocomplementemia, defined as low serum C3 and/or C4 concentrations, is common in patients with IgG4-related disease (IgG4-RD). While this has historically been linked with…
Abstract Number: 0279 • ACR Convergence 2025
Assessment of Baseline IgG4-RD Disease Characteristics and Impact Upon Safety and Efficacy of Inebilizumab: Results from the MITIGATE Study
Yoshiya Tanaka¹, Emma Culver², Arezou Khosroshahi³, Wen Zhang⁴, Kazuichi Okazaki⁵, Matthias Lohr⁶, nicolas schleinitz⁷, Xinxin Dong⁸, melissa rosen⁹, Sue Cheng⁸, Daniel Cimbora⁸ and John Stone¹⁰, ¹University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²John Radcliffe Hospital; University of Oxford, Oxford, United Kingdom, ³Emory University, Atlanta, GA, ⁴Peking Union Medical College Hospital, Dong Cheng Qu, China (People's Republic), ⁵Kansai Medical University Kori Hospital, Osaka, Japan, ⁶Karolinska Institutet, Stockholm, Sweden, ⁷Aix Marseille university, AP-HM, Marseille, France, ⁸Amgen, Thousand Oaks, CA, ⁹Amgen Inc., Thousand Oaks, CA, ¹⁰Massachusetts General Hospital , Harvard Medical School, Concord, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is a progressive, systemic, fibroinflammatory disease characterized by unpredictable and recurring flares, leading to organ damage and decreased quality of life.…

1
2
3
…
11
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].